Nanobiotix
Paris, France – October 2, 2025 – Nanobiotix (NASDAQ: NBTX) witnessed a significant surge in its stock price today, jumping 11.6%, following the announcement of highly encouraging initial data from a Phase 1 study of its lead product, JNJ-1900 (NBTXR3), in patients with locally advanced esophageal adenocarcinoma. This pivotal development, revealed
Immuneering Corporation
Boston, MA – September 27, 2025 – Immuneering Corporation (NASDAQ: IMRX) experienced a significant downturn in its stock value on September 25, 2025, with shares declining by approximately 13.3%. This notable drop came on the heels of the company's announcement and pricing of a substantial public stock offering, a
Eli Lilly
Eli Lilly (NYSE: LLY) is poised to further solidify its dominance in the burgeoning diabetes and weight loss markets following a cascade of overwhelmingly positive clinical trial results for its blockbuster injectable Mounjaro (tirzepatide) and its highly anticipated oral GLP-1 receptor agonist, Orforglipron. The findings, which demonstrate Mounjaro's
Viking Therapeutics
San Diego, CA – Viking Therapeutics (NASDAQ: VKTX) experienced a dramatic stock decline today following the release of disappointing clinical trial results for its highly anticipated oral tablet designed to treat obesity and other metabolic disorders. The sharp downturn, which saw the company's shares plummet by over 30% in